PAVmed shareholders re-elect directors, approve equity plan increase and stock issuance at annual meeting

PAVmed Inc.

Re-elected Lishan Aklog (7.15M for, 2.08M withheld) and Michael Glennon (7.22M for, 2.01M withheld) as Class C directors.
Approved issuance of common stock upon exercise of pre-funded warrants from Feb 2025 private placement (4.65M for, 0.29M against).
Approved amendment to 2014 equity plan increasing authorized shares by 2.5M, from 2,412,140 to 4,912,140 shares.
Advisory say-on-pay passed with 7.11M for, 0.38M against; ratification of Marcum LLP as auditor for 2025 passed with 14.22M for.
Turnout was ~77.2% of outstanding shares entitled to vote (common + preferred as-converted).

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.